Compounded Semaglutide vs Wegovy: What Actually Differs

Compounding exists so that a pharmacist can make a medication a patient needs when no approved product fits: a different strength, an allergen-free version, a liquid for someone who cannot swallow tablets. It is a legitimate, century-old part of pharmacy practice.

Two kinds of facility do it. A 503A pharmacy compounds for named patients on individual prescriptions, under state board oversight. A 503B outsourcing facility is registered with the FDA, follows manufacturing-grade standards, and can produce larger batches — but may only use a bulk ingredient if the FDA has determined there is a clinical need for it, or if the approved drug is in shortage.

Semaglutide ended up in mass compounding because of that shortage clause. Wegovy and Ozempic were on the FDA shortage list from 2022, which allowed both kinds of pharmacy to compound copies at scale. That window is what built the telehealth GLP-1 industry.

The shortage ended. As of April 1 2026 neither semaglutide nor tirzepatide is on the FDA's shortage list, and the enforcement discretion that came with the shortage — the period in which pharmacies could compound what were effectively copies of an available product — has been withdrawn.

Enforcement on marketing, February and March 2026. On February 6 2026 the FDA announced that it intends to act against mass-marketed, non-FDA-approved compounded GLP-1 drugs, including by restricting the bulk ingredients used to make them. It said companies cannot claim that a compounded product is a generic version of, or the same as, an FDA-approved drug, or that it is clinically proven to produce results, and it warned of seizure and injunction for violations. On March 3 2026 it made public warning letters, sent on February 20, to 30 telehealth companies over their marketing of compounded GLP-1s. The violations it named included claims implying sameness with FDA-approved products, and products branded with the telehealth company's own name in a way that implied it was the compounder.

The 503B bulks proposal, April 30 2026. The FDA then proposed going further: formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, on the finding that there is no clinical need for outsourcing facilities to compound them from bulk ingredients. The comment period, first set to close on June 29 2026, was extended to July 30 2026 at commenters' request. As of late September 2026 the proposal was still pending: the FDA had not announced a final determination.

What that proposal does not do is end compounding. It does not directly affect 503A pharmacies preparing patient-specific prescriptions: as one law-firm analysis puts it, the exclusion has no independent legal effect on their operations. Those pharmacies were always bound by the "essentially a copy" rule — they may not routinely reproduce a commercially available product — and that rule is now back in full force. A prescription for compounded semaglutide today has to be for a formulation that is meaningfully different from Wegovy for a documented clinical reason, not simply cheaper.

That is a narrower lane than the one the industry grew up in, and any provider still prescribing compounded semaglutide owes you a clear account of how their product fits inside it. It is also why this page does not describe compounded semaglutide as the same as, or equivalent to, Wegovy or any other brand.

Which pharmacy will fill it? Telehealth providers rarely publish this, and there are commercial reasons they do not — but the dispensing pharmacy is printed on every prescription label by law, and a provider should be able to tell you before you pay which pharmacy that will be, and that it is licensed in your state. "You'll see it on the label" is a fair answer. "We can't say" is not.

Base or salt? Approved semaglutide is the base form. Some compounders have used semaglutide sodium or semaglutide acetate — salt forms that the FDA has said are not the same active ingredient and are not eligible for compounding. This is the single most useful question on the list, and a provider who cannot answer it has told you something.

What testing stands behind each batch? A certificate of analysis for potency and sterility, from an independent laboratory, for the lot you are receiving. The FDA has logged adverse-event reports from compounded semaglutide, and a meaningful share of them trace to dosing errors made possible by vial-and-syringe supply rather than a fixed pen — which is a reason to want both good documentation and good instruction, not a reason to avoid the category.

We prescribe semaglutide as a clinical decision, not a product. Where a patient's insurance covers Wegovy, that is often the right route, and our Weight Loss Program Membership exists precisely so that supervision does not depend on where the medication comes from.

Where compounded semaglutide is prescribed, it is filled by a state-licensed compounding pharmacy in our platform's network and shipped directly to you. We do not publish the pharmacy's name on this page — the network can change, and a name on a web page is not a guarantee of anything. What you get instead is the answer to every question above, in writing, before you fill: your clinician will tell you which pharmacy will dispense your prescription, that it is licensed in your state, that the product is semaglutide base, and how to obtain the batch documentation for your lot. The pharmacy is also named on the label of everything you receive. If any of those answers is not forthcoming, do not fill the prescription, and tell us.

What we will not do is argue that compounded is "just as good" as approved. The evidence for semaglutide, including the STEP and SELECT trials, was generated with the approved, branded product. None of it was generated with a compounded product, and none of those results should be read as results for one.

We do not compete on price. Branded semaglutide is now also sold for cash, and in 2026 a branded product can cost less than a compounded one; what semaglutide costs has the dated figures for both. If price is the deciding factor, say so, and we will tell you honestly whether we are the right fit.